Prognostic relevance of DNMT3A R882 mutations in AML patients undergoing non-myeloablative conditioning hematopoietic stem cell transplantation

Bone Marrow Transplant. 2018 May;53(5):640-643. doi: 10.1038/s41409-017-0060-x. Epub 2018 Jan 15.

Affiliations

¹ Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany.
² Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany. Sebastian.Schwind@medizin.uni-leipzig.de.

PMID: 29335621
DOI: 10.1038/s41409-017-0060-x

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
DNA (Cytosine-5-)-Methyltransferases / genetics*
DNA Methyltransferase 3A
Hematopoietic Stem Cell Transplantation / methods*
Humans
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myeloid, Acute / therapy
Middle Aged
Mutation*
Prognosis
Retrospective Studies
Transplantation Conditioning / methods
Treatment Outcome

Substances

DNMT3A protein, human
DNA (Cytosine-5-)-Methyltransferases
DNA Methyltransferase 3A